Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Olema Pharmaceuticals Inc Market Cap
Based on ratings from 0 stock analysts, the Olema Pharmaceuticals Inc stock price is expected to increase by 145.79% in 12 months. This is calculated by using the average 12-month stock price forecast for Olema Pharmaceuticals Inc. The lowest target is $20 and the highest is $30. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedOLMA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Olema Pharmaceuticals Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on OLMA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of OLMA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anupam Rama JP Morgan | Overweight | $31 | Maintains | Aug 8, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $30 | Reiterates | Aug 7, 2024 |
| Matthew Biegler Oppenheimer | Outperform | $30 | Reiterates | Aug 7, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $30 | Reiterates | Jun 4, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $30 | Reiterates | May 15, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $28 | Maintains | May 9, 2024 |
| Richard Law Goldman Sachs | Buy | $24 | Initiates | Apr 2, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $25 | Maintains | Mar 12, 2024 |
| Matthew Biegler Oppenheimer | Outperform | $21 | Reiterates | Mar 12, 2024 |
| Yigal Nochomovitz Citigroup | Buy | $20 | Initiates | Jan 30, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $28 | Reiterates | Oct 11, 2023 |
| Anupam Rama JP Morgan | Overweight | $19 | Maintains | Sep 15, 2023 |
| Matthew Biegler Oppenheimer | Outperform | $21 | Reiterates | Sep 6, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $28 | Maintains | Sep 5, 2023 |
| Anupam Rama JP Morgan | Overweight | $16 | Maintains | Aug 10, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $22 | Maintains | Aug 9, 2023 |
| Richard Law Credit Suisse | Outperform | $18 | Maintains | Aug 9, 2023 |
| Matthew Biegler Oppenheimer | Outperform | $21 | Initiates | Jul 21, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $17 | Maintains | May 11, 2023 |
| Richard Law Credit Suisse | Outperform | $11 | Maintains | Mar 10, 2023 |
When did it IPO
2020
Staff Count
80
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Sean P. Bohen M.D., Ph.D.
Market Cap
$644.8M
In 2023, OLMA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that OLMA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Olema Pharmaceuticals granted stock options for 130,600 shares to five new employees as part of its 2022 Inducement Plan, effective September 3, 2024.
Why It Matters - Olema's stock option grants signal confidence in growth and talent acquisition, potentially enhancing company value. Increased employee stakes may align their interests with shareholders.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Olema Pharmaceuticals (Nasdaq: OLMA) will participate in an upcoming investor conference, focusing on targeted therapies for women's cancers.
Why It Matters - Olema's participation in an investor conference signals potential insights into its pipeline and strategy, which can influence stock valuation and investor sentiment.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Olema Pharmaceuticals reported its Q2 2024 financial results, focusing on targeted therapies for women's cancers, as of June 30, 2024.
Why It Matters - Olema Pharmaceuticals' Q2 financial results and corporate update signal progress in women's cancer therapies, potentially influencing investor confidence and stock performance.
Thu, 01 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Olema Pharmaceuticals (OLMA) has passed the "Recent Price Strength" screening, indicating potential for profit for investors interested in actively moving stocks.
Why It Matters - Olema Pharmaceuticals showing recent price strength indicates potential upward momentum, attracting investors seeking growth opportunities in trending stocks.
Wed, 05 Jun 2024
Sentiment - POSITIVE
Source - Finbold
Summary - GameStop (NYSE: GME) is gaining attention due to renewed trading activity, but investors should consider other potential short squeeze targets with recent sustainable gains.
Why It Matters - Renewed interest in GameStop may divert attention from other viable short squeeze opportunities, impacting market dynamics and potential investment strategies.
Tue, 28 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Olema Pharmaceuticals (Nasdaq: OLMA) announced its management will participate in upcoming investor conferences, focusing on targeted therapies for women's cancers.
Why It Matters - Olema Pharmaceuticals' participation in investor conferences signals potential for increased visibility and engagement, which can influence investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
